EHA 2025 Preview: Key Hematology Highlights to Watch

📅 Build your schedule around the topics that interest you. 📥 Download the EHA 2025_Preview_by_LucidQuest

Dive deeper

Ask Google AI

Ask ChatGPT

Ask Perplexity

Ask Grok

Key Topics From EHA 2025 Scientific Presentations

Leukemia

• Cyclophosphamide delivers 73% ORR and superior MRD clearance over methotrexate in LGL.

• GAIA/CLL13: BTK–VEN (GIV) 5-year PFS 81% in fit CLL, confirming time-limited regimens.

• Haplo vs mismatched-MUD transplants post-AML/ALL/MDS show equal 4-year OS ≈ 50%. ⚔️

Myeloma

• MIDAS multi-omics refines risk; hypoxia signature flags poor-prognosis MM.

• Trispecific ISB 2001 and CELMoD combos yield deep responses in heavily pre-treated RRMM.

• MRD-guided REMNANT intensifies frontline gains. 🔬

Lymphoma

• Acimtamig + Allo-NK posts high ORR in r/r cHL.

• MRD negativity via PhasED-Seq predicts DLBCL survival.

• Pelabresib + ruxolitinib improves MF fibrosis and anemia. 🛡️

Transplant / GVHD

• Target-dose ATG cuts CMV and speeds reconstitution.

• Fecal microbiotherapy (MaaT013) rescues GI-aGVHD after ruxolitinib.

• Axatilimab shows promise in chronic GVHD. 🏥

AML / MDS

• Oral decitabine/cedazuridine + VEN matches IV outcomes.

• Menin inhibitors (ziftomenib, revumenib) achieve high CRc/MRD-neg in NPM1/KMT2A AML.

• DAC+HAAG beats 7+3 in adverse-risk AML for MRD and 2-year OS. ⚡️

Autoimmune Cytopenias

• Avatrombopag sustains platelets in pediatric ITP.

• Sovleplenib (Syk) revives refractory AIHA.

• Rilzabrutinib (BTK-i) boosts ITP responses. 🌱

Bone Marrow Failure / PNH

• Iptacopan, pegcetacoplan, crovalimab secure transfusion-free control.

• Hetrombopag + CsA elevates NSAA response.

• Luspatercept eases anemia in older NSAA. 💉

Classical Hodgkin Lymphoma (cHL)

• PET-adapted protocols maintain PFS/OS with lower late toxicity.

• Nivo-AVD delivers near-universal metabolic responses in frontline, while BBG salvage readies patients for transplant. 🔥

Artificial Intelligence and Machine Learning at EHA 2025

AI_Diagnostics

• Flow-cytometry and RNA-seq models classify AML, T-ALL, mastocytosis, neutropenia with high accuracy. 🤖

Prognostic ML

• Multivariate algorithms outperform IPSS-R in MDS and integrate genomics for AML/MPN risk. 📊

Digital Pathology

• CIF mapping standardises fibrosis/blast counts in BMT slides across centres. 🖥️

Therapy Predict

• ML forecasts HMA response in MDS, CAR-T toxicity, and asciminib benefit in CML. 🧩

Bleeding Risk AI

• Models flag AML/ITP hemorrhage risk and evaluate VWD/AIHA drug efficacy. 🩺

Explainable AI

• SmartCytoFlow 2.0 delivers GPT-4o rationale-based outputs to boost clinician trust. 💡

Access Tech

• Smartphone AI screens hemoglobinopathies in low-resource settings, widening early detection. 🌍

📅 Build your schedule around the topics that interest you.

📥 Download the EHA 2025_Preview_by_LucidQuest

Contact us for end-to-end conference coverage.